Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on ...

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Piper Sandler lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $533 from $535 and keeps an Overweight rating on the shares ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a decline, ending the day at $439.62 which represents a decrease of $-0.11 or -0.03% from the prior close of $439.73. The stock opened at $438.73 and ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.